Corcept Therapeutics Incorporated (CORT)

Market Cap	3.29B
Revenue (ttm)	523.53M
Net Income (ttm)	117.19M
Shares Out	104.11M
EPS (ttm)	1.06
PE Ratio	29.77
Forward PE	29.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	887,610
Open	32.67
Previous Close	32.67
Day's Range	31.52 - 32.93
52-Week Range	20.84 - 35.22
Beta	0.46
Analysts	Strong Buy
Price Target	41.40 (+31.18%)
Earnings Date	Jul 31, 2024

About CORT

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 352
• Stock Exchange: NASDAQ
• Ticker Symbol: CORT

Financial Performance

In 2023, CORT's revenue was $482.38 million, an increase of 20.04% compared to the previous year's $401.86 million. Earnings were $105.50 million, an increase of 4.15%.

Analyst Forecast

According to 5 analysts, the average rating for CORT stock is "Strong Buy." The 12-month stock price forecast is $41.4, which is an increase of 31.18% from the latest price.

Price Target

$41.4

(31.18% upside)

Analyst Consensus: Strong Buy